Alembic share news, announcements and annual reports
NSE: ALEMBICLTDBSE: 506235RealtySmall Cap
Alembic Limited · Formerly Alembic Chemical Works Co. · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1934 on BSE, Sep 1999 on NSE
Last close ₹89.31up ₹1.72 (1.96%)BSE ₹89.45
Share price at the NSE close on 29 Oct 2026. Previous close ₹87.59.
29 Oct: open ₹87.00, high ₹89.49, low ₹86.86
52-week range of traded prices to 29 Oct 2026
₹70.46Low, 30 Mar 2026₹117.72High, 3 Sep 2026
- Next results date: the board meets on 6 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹2,293 Cr1,101st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 7.15
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.94
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.69%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,69,68150.2% delivered
Alembic board meetings
116 filed, newest first. Page 2 of 3.
Oct 2018
23 Oct · Board meeting
Not held on this date
Sep 2018
11 Sep · Board meeting
Aug 2018
7 Aug · Board meeting
Jul 2018
30 Jul · Board meeting
May 2018
17 May · Board meeting
Jan 2018
23 Jan · Board meeting
Oct 2017
Jul 2017
28 Jul · Board meeting
May 2017
Jan 2017
19 Jan · Board meeting
Oct 2016
Aug 2016
Apr 2016
Jan 2016
Oct 2015
Aug 2015
Apr 2015
Jan 2015
13 Jan · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended December 31, 2014.
Nov 2014
5 Nov · Board meeting
Board of Directors of Alembic Ltd. at its meeting held on November 05, 2014 has taken following decisions: (1). Appointment of Mr. Abhijit Joshi as an Additional Director of the Company. (2) Reconstitution of the Audit Committee. The composition of the Audit Committee is as under: 1. Name of the Director - Mr. Milin Mehta, Catergory- Independent, Designation - Chairman. 2. Name of the Director- Mr. C. P. Buch, Category- Independent, Designation - Member. 3. Name of the Director: Mr. R. C. Saxena , Category- Independent, Designation - Member.
Oct 2014
27 Oct · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2014.
Aug 2014
4 Aug · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2014. Further, the Company has also informed that the trading window shall remain closed from August 10, 2014 to August 14, 2014 for the above purpose.
Apr 2014
28 Apr · Board meeting
Inter alia, to transact following business: 1. To consider and approve Audited Financial statements of the Company for the Financial year ended March 31, 2014 2. To consider and recommend dividend, if any, for the Financial Year ended March 31, 2014. Further, the Company has also informed that the trading window shall remain closed from May 05, 2014 to May 07, 2014 for the above purpose.
Jan 2014
22 Jan · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2013. Further, that the trading window shall remain closed from January 27, 2014 to January 31, 2014 for the above purpose.
Oct 2013
29 Oct · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2013.
Aug 2013
12 Aug · Board meeting
Following decisions have been taken at the Board meeting : 1). The Board has approved, subject to approval of shareholders, increase in authorized capital from present Rs. 30 Crores divided into 15,00,00,000 Equity Shares of Rs. 2 each to Rs. 60 Crores divided into 30,00,00,000 Equity Shares of Rs. 2 each. 2). The Board has approved addendum to the notice convening Annual General Meeting to be circulated to the members for the above purpose.
Jul 2013
29 Jul · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2013.
Apr 2013
25 Apr · Board meeting
Board of Directors of the Company at its meeting held on April 24, 2013, have taken the following decisions: (a) The Board has appointed Mr.Udit Amin as Additional Director and Director & President-Real Estate Business w.e.f. April 24, 2013. Further Mr.Udit Amin has been designated as CEO of the Company w.e.f. April 24, 2013. (b) Mr. Ashok Tulankar has resigned as Manager of the Company w.e.f. April 30, 2013, however, he shall continue as Non-Executive Director of the Company.
Jan 2013
25 Jan · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended December 31, 2012
Oct 2012
25 Oct · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the Quarter ended September 30, 2012.
Jul 2012
26 Jul · Board meeting
Inter alia to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2012.
Apr 2012
24 Apr · Board meeting
Inter-alia to consider and approve Audited Financial statements of the Company for the financial year ended March 31, 2012.
Jan 2012
25 Jan · Board meeting
Company had informed the Exchange regarding a Board meeting to be held on February 07, 2012 inter aila to consider and approve the Unaudited Financial Results of the Company for the Quarter ended December 31, 2011. The Company has now informed the Exchange that the Meeting of Board of Directors of the Company to consider and approve, inter alia the Unaudited Financial Results of the Company for the Quarter ended December 31, 2011, is rescheduled and now shall be held on February 14, 2012.Not held on this date
19 Jan · Board meeting
Inter aila to consider and approve the Unaudited Financial Results of the Company for the Quarter ended December 31, 2011.
Oct 2011
10 Oct · Board meeting
Inter alia, to consider and approve the Un-audited Financial Results of the Company for the quarter ended on September 30, 2011.
Jul 2011
7 Jul · Board meeting
To consider and approve, inter-alia, the Un-Audited Financial Results for the quarter ended on June 30, 2011.
Apr 2011
25 Apr · Board meeting
To consider and approve, inter-alia, the Audited Financial Results for the year ended on March 31, 2011.4 Apr · Board meeting
Board of Directors of the Company at its meeting held on March 31, 2011, inter alia, transacted the following : The Board of Directors of the Company has been reconstituted as under : (1) Mr. Chirayu Amin - Chairman; (2) Mrs. Malika Amin - Whole-time Director; (3) Dr. B. R. Patel, Director; (4) Mr. Milin Mehta, Director; (5) Mr. Sanjay Bhatt, Director & Company Secretary & Compliance Officer.
Mar 2011
23 Mar · Board meeting
Meeting of the Board of Directors of Alembic Limited and Alembic Pharmaceuticals Limited (name changed from Alembic Pharma Limited) will be held on March 31, 2011 to consider and approve reconstitution of Board due to demerger and considering other agenda items relating to demerger including fixing of record date for ascertaining the eligibility of the members to receive the equity shares of Alembic Pharmaceuticals Limited as per the Scheme of Arrangement approved by the Hon'ble High Court of Gujarat vide order dated January 24, 2011.
Jan 2011
14 Jan · Board meeting
Company had informed the Exchange that a meeting of the Board of Directors of the Company will be held on January 21, 2011 to consider and approve, inter-alia, the Un-Audited Financial Results for the third quarter ended on December 31, 2010 (October 01, 2010 to December 31, 2010). The Company has now informed the Exchange that the date of the Board Meeting is postponed. The meeting of the Board of Directors of the Company will be held on January 25, 2011 (instead of January 21, 2011) to consider and approve, inter-alia, the Un-Audited Financial Results for the third quarter ended on December 31, 2010 (October 01, 2010 to December 31, 2010).Not held on this date
11 Jan · Board meeting
To consider and approve, inter-alia, the Un-Audited Financial Results for the third quarter ended on December 31, 2010 (October 01, 2010 to December 31, 2010).
Oct 2010
11 Oct · Board meeting
To consider and approve, inter-alia, the Un-audited Financial Results for the second quarter ended on September 30, 2010 (July 01, 2010 to September 30, 2010).
Jul 2010
19 Jul · Board meeting
To consider and approve, inter-alia, the Un-audited Financial Results for the quarter ended on June 30, 2010 (April 01, 2010 to June 30, 2010).
Jun 2010
29 Jun · Board meeting
Board of Directors of the Company at its meeting on June 29, 2010 has, in-principle, approved the demerger of Pharmaceutical Undertaking of the Company and to merge the said Undertaking into Alembic Pharma Limited, a wholly owned subsidiary company of Alembic Limited with effect from appointed date i.e. April 1, 2010, subject to the requisite approvals including Shareholders, Creditors, Stock Exchanges, the Hon'ble High Court of Gujarat and other authorities, as may be required for the purpose. The following Share Exchange Ratio has been determined: The existing Shareholders of Alembic Limited will get 1 (one) equity share having face value of Rs. 2/- each in the Resulting Company i.e. Alembic Pharma Limited (APL) for every 1 equity shares having face value of Rs. 2/- each held by them in the Company. This will be in addition to the equity shares already held by the shareholders in Alembic Limited. The Scheme of arrangement also envisages re-organisation of Vadodara Undertaking including re-valuation of assets.25 Jun · Board meeting
To, inter alia, consider the proposal for corporate re-organisation (including de-merger of the division, etc).